Withdrawal of statins increases event rates in patients with acute coronary syndromes

Area of Science:

• Cardiology
• Pharmacology

Background:

• HMG-CoA reductase inhibitors (statins) are known to reduce cardiac events in stable coronary heart disease.
• Statin withdrawal during acute coronary syndromes (ACS) may negatively impact vascular function beyond lipid levels, potentially increasing cardiac events.

Purpose of the Study:

• To investigate the effect of statin therapy continuation versus discontinuation on cardiac event rates in patients with ACS.
• To determine if the effects of statins in ACS are independent of lipid-lowering.

Main Methods:

• Analysis of 1616 patients from the PRISM study with coronary artery disease and recent chest pain.
• Categorization into groups: no statin therapy, continued statin therapy, and discontinued statin therapy post-hospitalization.
• 30-day follow-up recording of death and nonfatal myocardial infarction.

Main Results:

• Statin therapy was associated with a significantly reduced 30-day event rate compared to no statin use (adjusted HR 0.49).
• Statin discontinuation post-admission increased cardiac risk significantly compared to continuation (HR 2.93) and tended to be higher than never receiving statins (HR 1.69).
• These effects were observed early (first week) and were independent of cholesterol levels. Continuation of statin therapy was an independent predictor of better patient outcome.

Conclusions:

• Pretreatment with statins in ACS patients is linked to improved clinical outcomes.
• Discontinuation of statin therapy following symptom onset eliminates the protective benefits, increasing cardiac risk.